IRIS Institutional Research Information System - OPENBS Open Archive UniBS

ANDREOLI, Laura
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.320
EU - Europa 7.749
AS - Asia 7.454
SA - Sud America 1.743
AF - Africa 238
OC - Oceania 22
Continente sconosciuto - Info sul continente non disponibili 17
AN - Antartide 1
Totale 30.544
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.110
SG - Singapore 2.612
DE - Germania 2.249
CN - Cina 2.198
BR - Brasile 1.450
UA - Ucraina 1.201
HK - Hong Kong 980
IT - Italia 886
PL - Polonia 776
RU - Federazione Russa 633
VN - Vietnam 620
FI - Finlandia 457
FR - Francia 453
GB - Regno Unito 403
TR - Turchia 303
IE - Irlanda 239
IN - India 178
BD - Bangladesh 115
AR - Argentina 109
CA - Canada 95
SE - Svezia 89
MX - Messico 74
ZA - Sudafrica 73
NL - Olanda 71
IQ - Iraq 65
EC - Ecuador 52
JP - Giappone 51
ID - Indonesia 47
ES - Italia 45
NG - Nigeria 39
AT - Austria 38
PK - Pakistan 38
CO - Colombia 34
SA - Arabia Saudita 33
CZ - Repubblica Ceca 31
VE - Venezuela 30
UZ - Uzbekistan 27
MA - Marocco 26
EG - Egitto 23
AU - Australia 21
BE - Belgio 21
JO - Giordania 21
PY - Paraguay 20
AE - Emirati Arabi Uniti 18
CL - Cile 18
DZ - Algeria 16
PH - Filippine 16
EU - Europa 15
KE - Kenya 15
CH - Svizzera 14
GR - Grecia 14
PE - Perù 14
HR - Croazia 13
LT - Lituania 13
TH - Thailandia 13
AL - Albania 12
KZ - Kazakistan 12
IL - Israele 11
MK - Macedonia 10
PT - Portogallo 10
DK - Danimarca 9
ET - Etiopia 9
JM - Giamaica 9
NP - Nepal 9
RS - Serbia 9
TN - Tunisia 9
UY - Uruguay 9
SK - Slovacchia (Repubblica Slovacca) 8
BG - Bulgaria 7
GE - Georgia 7
HU - Ungheria 7
LY - Libia 7
RO - Romania 7
AZ - Azerbaigian 6
BH - Bahrain 6
CR - Costa Rica 6
DO - Repubblica Dominicana 6
KR - Corea 6
LB - Libano 6
PS - Palestinian Territory 6
BO - Bolivia 5
HN - Honduras 5
KG - Kirghizistan 5
KW - Kuwait 5
LU - Lussemburgo 5
MY - Malesia 5
SN - Senegal 5
SY - Repubblica araba siriana 5
TW - Taiwan 5
BY - Bielorussia 4
CI - Costa d'Avorio 4
IR - Iran 4
KH - Cambogia 4
LV - Lettonia 4
NO - Norvegia 4
SV - El Salvador 4
AM - Armenia 3
BB - Barbados 3
LK - Sri Lanka 3
OM - Oman 3
Totale 30.503
Salva come PNG Salva come JPEG
Città #
Fairfield 1.489
Singapore 1.357
Woodbridge 1.174
Ashburn 1.172
Hong Kong 972
Houston 832
Jacksonville 830
Warsaw 766
The Dalles 574
Seattle 568
Cambridge 544
San Jose 522
Wilmington 512
Ann Arbor 491
Beijing 466
Princeton 439
New York 383
Chandler 346
Helsinki 291
Istanbul 243
Dublin 238
Lauterbourg 234
Los Angeles 234
Nanjing 227
Ho Chi Minh City 200
Munich 149
São Paulo 144
Brescia 135
Hanoi 133
Dallas 129
Moscow 117
Milan 113
Redondo Beach 107
Nanchang 102
Nürnberg 102
San Diego 101
Buffalo 94
Des Moines 94
Changsha 86
Council Bluffs 86
Shanghai 83
San Francisco 80
Chicago 76
Shenyang 69
Hebei 65
London 64
Lancaster 62
Santa Clara 59
Rio de Janeiro 52
Turku 52
Nuremberg 51
Orem 51
Tokyo 46
Chennai 44
Jinan 42
Johannesburg 39
Abuja 37
Belo Horizonte 34
Tianjin 33
Toronto 33
Dearborn 32
Hangzhou 32
Jiaxing 32
Denver 31
Atlanta 30
Porto Alegre 29
Brooklyn 28
Haiphong 28
Poplar 28
Zhengzhou 28
Amsterdam 27
Bergamo 27
Curitiba 27
Da Nang 27
Guangzhou 27
Dhaka 26
Frankfurt am Main 26
Rome 26
Brasília 25
Phoenix 25
Tashkent 25
Verona 25
Dong Ket 24
Mexico City 24
Biên Hòa 23
Manchester 23
Romola 23
Boardman 21
Kunming 21
Montreal 21
Amman 19
Baghdad 19
Brussels 19
Guayaquil 19
Brno 18
Lanzhou 18
Mumbai 18
Stockholm 18
Charlotte 16
Goiânia 16
Totale 18.839
Salva come PNG Salva come JPEG
Nome #
9A.07: CARDIOVASCULAR TARGET ORGAN DAMAGE IN PREMENOPAUSAL SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AND IN CONTROLS. ARE THERE ANY DIFFERENCES? 338
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome 305
Role of guanylate binding protein-1 in vascular defects associated with chronic inflammatory diseases. 293
The Pathogenicity of Anti-β2GP1-IgG Autoantibodies Depends on Fc Glycosylation 253
Aicardi-Goutieres syndrome, a rare neurological disease in children: a new autoimmune disorder? 232
Long-term outcome of children of rheumatic disease patients 231
Sine causa tetraparesis: A pilot study on its possible relationship with interferon signature analysis and Aicardi Goutières syndrome related genes analysis 227
COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case–control study 214
SINDROME DA ANTICORPI ANTIFOSFOLIPIDI E LESIONI PUNTIFORMI DELLA SOSTANZA BIANCA ALLA RISONANZA MAGNETICA. QUAL E' IL LORO SIGNIFICATO? VALUTAZIONE DI 169 PAZIENTI CON MANIFESTAZIONI NEUROLOGICHE 204
14th International Congress on Antiphospholipid Antibodies Task Force report on obstetric antiphospholipid syndrome 204
Antirheumatic drugs and reproduction in women and men with chronic arthritis. 204
The role of second trimester uterine artery Doppler in pregnancies with systemic lupus erythematosus 202
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy 195
Trichostatin A blocks type I interferon production by activated plasmacytoid dendritic cells. 191
14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends 191
A comprehensive review of the clinical approach to pregnancy and systemic lupus erythematosus 188
Effector T-cells are expanded in systemic lupus erythematosus patients with high disease activity and damage indexes 186
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) 186
Typing TREX1 Gene In Patients With Systemic Lupus Erythematosus. 183
Anti-IFI16 antibodies and their relation to disease characteristics in systemic lupus erythematosus. 182
Macrophage activation syndrome in adult systemic lupus erythematosus: Report of seven adult cases from a single Italian rheumatology center 182
Anti-phospholipid antibodies 181
Anti-cardiolipin and anti-beta2-glycoprotein I antibodies: performance of new commercial ELISA kits. 178
Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences? 177
Children born to SLE and APS mothers 175
Management of thrombotic and obstetric antiphospholipid syndrome: A systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults 173
A 24-month prospective study on the efficacy and safety of two different monthly regimens of vitamin D supplementation in pre-menopausal women with systemic lupus erythematosus 172
Autoantibodies' titre modulation by anti-BlyS treatment in systemic lupus erythematosus. 171
Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab 167
Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome 167
25 years of the antiphospholipid syndrome: lights and shadows on the primary prophylaxis of asymptomatic patients with confirmed positivity of antiphospholipid antibodies. 166
Antiphospholipid antibodies mediate autoimmunity against dying cells. 166
Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study 165
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 163
Inflammatory molecules: A target for treatment of systemic autoimmune diseases. 162
Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years 162
Pregnancy implications for systemic lupus erythematosus and the antiphospholipid syndrome 160
Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality 160
Validity of the rheumatoid arthritis impact of disease (RAID) score and definition of cut-off points for disease activity states in a population-based European cohort of patients with rheumatoid arthritis 160
The effects of lupus and antiphospholipid antibody syndrome on foetal outcomes 159
Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a 'systemic disease'. 156
Are the autoimmune/inflammatory syndrome induced by adjuvants (ASIA) and the undifferentiated connective tissue disease (UCTD) related to each other? A case-control study of environmental exposures 153
Risk factors for adverse maternal and fetal outcomes in women with confirmed aPL positivity: Results from a multicenter study of 283 pregnancies 152
Long-term outcome of children born from mothers with autoimmune diseases 152
Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications? 151
Exosome-delivered microRNAs promote IFN-α secretion by human plasmacytoid DCs via TLR7 150
APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. 149
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study 149
Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? 148
Antiphospholipid antibody profile: implications for the evaluation and management of patients. 148
Beyond the "syndrome": antiphospholipid antibodies as risk factors. 147
ANTI-BETA2 GLYCOPROTEIN I-DOMAIN 1 AUTOANTIBODIES: COMPARISON BETWEEN TWO METHODS OF DETECTION 147
State of the art: Reproduction and pregnancy in rheumatic diseases. 147
European multicentre pilot survey to assess vitamin D status in rheumatoid arthritis patients and early development of a new Patient Reported Outcome questionnaire (D-PRO) 147
Long-term neurodevelopmental outcome of children born to prospectively followed pregnancies of women with systemic lupus erythematosus and/or antiphospholipid syndrome 147
Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: 'Colchicine treatment in community healthcare setting to prevent severe COVID-19' by Della-Torre et al 147
Are the current attempts at standardization of antiphospholipid antibodies still useful? Emerging technologies signal a shift in direction. 146
Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. 146
Autoantibodies against galectin-2 peptides as biomarkers for the antiphospholipid syndrome. 146
Phenotype modifications of T-cells and their shift toward a Th2 response in patients with systemic lupus erythematosus supplemented with different monthly regimens of vitamin D 146
Pregnancy in autoimmune rheumatic diseases: the importance of counselling for old and new challenges. 145
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome 145
Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome 145
EFFICACY AND SAFETY OF CYCLOSPORINE-A DURING PREGNANCY IN AUTOIMMUNE DISEASES 144
PROSPECTIVELY FOLLOWED PREGNANCIES IN PATIENTS WITH SYSTEMIC VASCULITIS: STILL MANY PROBLEMS ON BOTH FOETAL AND MATERNAL SIDE 143
An EULAR study group pilot study on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases 143
High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. 142
Management of recurrent thrombosis in antiphospholipid syndrome 142
Systemic vasculitis and pregnancy: a multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies 142
Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases 142
Pregnancy in patients with autoimmune disease: A reality in 2016 141
Development of automated assays for anticardiolipin antibodies determination: addressing antigen and standardization issues. 140
Exploring Autoimmunity in a Cohort of Children with Genetically Confirmed Aicardi–Goutières Syndrome 140
Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. 140
Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study 140
Primary antiphospholipid syndrome evolving into systemic lupus erythematosus: may antinucleosome antibodies be predictive? 139
Predictors of maternal and fetal complications in SLE patients: a prospective study 139
Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. 137
Subpopulations of anti-β₂glycoprotein I antibodies with different pathogenic potential: fine specificity against the domains of β₂glycoprotein I 136
Neonatal effects of maternal antiphospholipid syndrome. 135
I polimorfismi della metilentetraidrofolatoreduttasi (MTHFR) nel trattamento con methotrexate di pazienti con artrite reumatoide. Revisione della letteratura ed esperienza personale. 135
Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy 133
The 2016 classification criteria for primary Sjogren's syndrome: What's new? 133
The Efficacy and Safety of Cyclosporin A in Pregnant Patients with Systemic Autoimmune Diseases 132
Long-term treatment with tocilizumab in giant cell arteritis: efficacy and safety in a monocentric cohort of patients 132
DOMAIN 1 IS THE MAIN SPECIFICITY OF ANTI-BETA2GPI ANTIBODIES IN SYSTEMIC AUTOIMMUNE DISEASES 131
Infertility in women with systemic autoimmune diseases 131
IL COMPLEMENTO NELLA GRAVIDANZA DI DONNE AFFETTE DA SINDROME DA ANTICORPI ANTIFOSFOLIPIDI PRIMARIA 130
METODICHE AUTOMATIZZATE PER ANTICORPI ANTINUCLEO (ANA): E' POSSIBILE SOSTITUIRE L'IMMUNOFLUORESCENZA INDIRETTA? 130
A PROSPECTIVE STUDY IN PREMENOPAUSAL WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS SUPPLEMENTED WITH TWO DIFFERENT REGIMES OF VITAMIN D: EFFICACY AND SAFETY AT SIX MONTHS OF FOLLOW-UP 130
DECREASED TITER OF ANTI-CCP ANTIBODIES AND RHEUMATOID FACTOR AND REDUCTION OF POSTSWITCH MEMORY B CELLS AFTER ABATACEPT TREATMENT FOR RHEUMATOID ARTHRITIS 130
Small extracellular vesicle-delivered microRNAs promote IFN-alpha secretion by plasmacytoid DCs via TLR7 130
Low levels of vitamin D are common in primary antiphospholipid syndrome with thrombotic disease. 129
Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy. 129
Vitamin D and antiphospholipid syndrome. 127
Clinical significance of IgA anti-cardiolipin and IgA anti-β2glycoprotein I antibodies. 126
A multicentre study of 244 pregnancies in undifferentiated connective tissue disease: maternal/fetal outcomes and disease evolution 125
Belimumab decreases flare rate and hinders the expected damage progression in patients with active systemic lupus erythematosus 124
Domain 1 Is The Main Specificity Of Anti-b2glycoprotein I Antibodies In Systemic Autoimmune Diseases. 122
The antiphospholipid syndrome in patients with systemic lupus erythematosus 122
Totale 16.150
Salva come PNG Salva come JPEG
Categoria #
all - tutte 144.298
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 144.298
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021961 0 0 0 0 0 0 0 0 0 473 312 176
2021/20221.763 114 280 54 102 20 102 57 132 103 206 172 421
2022/20231.285 248 16 32 58 125 377 5 107 176 4 65 72
2023/20241.814 108 64 144 158 66 345 56 78 456 33 26 280
2024/20254.520 84 71 66 530 408 411 509 247 392 351 915 536
2025/20268.971 856 1.383 744 1.497 911 608 1.351 371 549 701 0 0
Totale 30.996